Complex brain disorders like schizophrenia may have multifactorial origins related to mis-timed heritable and environmental factors interacting during neurodevelopment. Infections, inflammation, and autoimmune diseases are over-represented in schizophrenia leading to immune system-centered hypotheses. Complement component C4 is genetically and neurobiologically associated with schizophrenia, and its dual activity peripherally and in the brain makes it an exceptional target for biomarker development. Studies to evaluate the biomarker potential of plasma or serum C4 in schizophrenia do so to understand how peripheral C4 might reflect central nervous system-derived neuroinflammation, synapse pruning, and other mechanisms. This effort, however, has produced mostly conflicting results, with peripheral C4 sometimes elevated, reduced, or unchanged between comparison groups. We undertook a pilot biomarker development study to systematically identify sociodemographic, genetic, and immune-related variables (autoimmune, infection-related, gastrointestinal, inflammatory), which may be associated with plasma C4 levels in schizophrenia (SCH; n = 335) and/or in nonpsychiatric comparison subjects (NCs; n = 233). As with previously inconclusive studies, we detected no differences in plasma C4 levels between SCH and NCs. In contrast, levels of general inflammation, C-reactive protein (CRP), were significantly elevated in SCH compared to NCs (ANOVA, F = 20.74, p < 0.0001), suggestive that plasma C4 and CRP may reflect different sources or causes of inflammation. In multivariate regressions of C4 gene copy number variants, plasma C4 levels were correlated only for C4A (not C4B, C4L, C4S) and only in NCs (R Coeff = 0.39, CI = 0.01–0.77, R2 = 0.18, p < 0.01; not SCH). Other variables associated with plasma C4 levels only in NCs included sex, double-stranded DNA IgG, tissue-transglutaminase (TTG) IgG, and cytomegalovirus IgG. Toxoplasma gondii IgG was the only variable significantly correlated with plasma C4 in SCH but not in NCs. Many variables were associated with plasma C4 in both groups (body mass index, race, CRP, N-methyl-D-aspartate receptor (NMDAR) NR2 subunit IgG, TTG IgA, lipopolysaccharide-binding protein (LBP), and soluble CD14 (sCD14). While the direction of most C4 associations was positive, autoimmune markers tended to be inverse, and associated with reduced plasma C4 levels. When NMDAR-NR2 autoantibody-positive individuals were removed, plasma C4 was elevated in SCH versus NCs (ANOVA, F = 5.16, p < 0.02). Our study was exploratory and confirmation of the many variables associated with peripheral C4 requires replication. Our preliminary results point toward autoimmune factors and exposure to the pathogen, T. gondii, as possibly significant contributors to variability of total C4 protein levels in plasma of individuals with schizophrenia.

Schizophrenia is a neurodevelopmental disorder with an etiology and pathophysiology increasingly linked to interacting environmental and genetic immune sources [1‒4]. Pathogen exposures, autoimmune comorbidities, gut dysbiosis, acute inflammatory episodes, and chronic low-grade inflammation are all implicated risk factors [5‒17]. The specific mechanism(s) underlying inflammation and driving the immune component of this complex brain disorder, however, has been difficult to identify. Distinguishing sub-categories of the operative inflammatory processes in schizophrenia is not only important from a mechanistic perspective but also as a guide if anti-inflammatory drugs are being considered for use in this disorder. For example, inflammatory pathologies or comorbidities are not managed using the same interventions, and each inflammatory type requires a different treatment (i.e., antibiotics, antivirals, antifungals, non-steroidal anti-inflammatories, and steroidal-derived immune inhibition compounds).

The complement system has been implicated in schizophrenia etiology and pathophysiology for a long time, and its components contribute a first line of defense against antigens, while also inducing inflammation as part of the innate immune response [18‒25]. Schizophrenia is also highly heritable, and the search for susceptibility genes has focused on immuno-genetically relevant loci, among other factors [26, 27]. Evidence for a genetic association of the complement component, C4, and its structural isoforms, C4A and C4B, with schizophrenia has been re-invigorated into an intriguing model connecting increasing C4 copy number variants (CNVs) with C4A overexpression in the brain, and excessive synapse pruning [28].

Much research effort has been directed at scrutinizing and perfecting this C4 model to better understand how peripheral functions of C4 are related to complement mechanisms operative in the central nervous system (CNS) in individuals with schizophrenia. While the aims may differ from study to study, a shared goal has been a desire to develop peripheral biomarkers that reflect pathologies relevant to schizophrenia. Such functional endpoints that could be linkable to a plasma C4 biomarker include abnormal synaptic pruning, cortical thinning, neuropil contraction, and dendritic spine deficiencies [28‒37]. Future potential biomarker goals might include detection of neuroinflammation, more rapid identification of early psychoses, identification of cognitive deficits and other symptomatology, choice of treatment, and monitoring of treatment efficacies [38‒43]. Interrogations of peripheral C4, however, have produced remarkably mixed results, with peripheral C4 sometimes elevated, sometimes reduced and sometimes unchanged in schizophrenia versus comparison groups [33, 36, 38, 40, 44‒50].

Analyses of cerebrospinal fluid (CSF) may offer a more broad perspective, given the functional role of this body fluid as a link between peripheral and CNSs. However, studies of C4 levels in CSF samples from patients with schizophrenia seem as similarly conflicted as the plasma and serum studies. For example, CSF C4, but not plasma C4, was increased in individuals with schizophrenia compared to controls, and this group difference was only detectable when comparisons were corrected for age and sex [51]. Investigators found C4A elevations in CSF from first episode psychosis patients who developed schizophrenia (FEP-SCZ) compared to healthy control group levels and levels from FEP patients who did not develop schizophrenia [52]. C4B levels in CSF were not different between groups, as expected if the C4A locus is driving the C4 genetic association in schizophrenia. Of note, C4B and related gene deficiencies have been reported associated with schizophrenia [19, 33]. In a study of individuals at clinical high risk for psychosis, antipsychotic-naïve FEP and healthy controls, an array of complement proteins including C4 was elevated in serum of both patient groups compared to controls, but no inter-group differences were present in CSF. Furthermore, body mass index (BMI) levels and storage times were associated with CSF complement measures [53].

Before we can effectively design a biomarker to study synapse pruning and related outcomes, we must understand why peripheral plasma or serum C4 levels are not straightforward reflections of peripheral inflammation. The inconsistencies repeatedly encountered with studies of C4 in plasma or serum are probably driven by many factors including heterogeneities of psychiatric diagnoses, problematic study designs and multiple types and sources of inflammation that are not uniformly measurable by a single inflammatory marker. Inconclusive findings may also result from intrinsic and extrinsic factors that interfere, confound, or otherwise co-associate with plasma C4 levels in schizophrenia and comparison groups. Published studies already are documenting significant associations of age, sex, and race with a variety of C4 and related measures [39, 51, 54‒56].

Our goal was to begin an exploratory C4 biomarker development process by systematically identifying factors that might contribute to peripheral C4 levels in schizophrenia and a nonpsychiatric comparison group. We examined plasma C4 associations with standard sociodemographic variables and clinical factors (age, BMI, socioeconomic status, race, sex, and cigarette smoking), C4 gene CNVs (C4A, C4B, C4L, C4S), and categories of immune variables related to autoimmunity, infections, gastrointestinal (GI) dysbiosis, and general inflammation. Details regarding the variables chosen are further described in the Methods section. Ultimately, we hope that this exploratory work will lead to well-matched prospective studies to determine if it is worthwhile pursuing peripheral C4 as a biomarker of neuroinflammation, synapse pruning, and other related neural mechanisms.

Study Population

Participants were recruited at Sheppard Pratt in Baltimore, MD, USA as part of a long-term, ongoing study of schizophrenia. Started in 1999, this cohort is a source of sociodemographic, clinical, and other types of data and biospecimens with an overall goal to understand the immune components of major psychiatric disorders. For our current study, we reviewed the database and identified individuals with schizophrenia (SCH; n = 335) and a non-psychiatric comparison group (NCs; n = 233) for whom we had plasma C4 biomarker data. Sample sizes varied for some of the follow-up multivariate comparisons, and these are so noted in the relevant sections. Basic sociodemographic and other standard data typically applied to studying psychoimmunology-derived cohorts are shown in Table 1.

Table 1.

Standard sociodemographic and other variables in the study populations

Sociodemographic/other test variableNCs (n = 233)SCH (n = 335)Test statp value
Age (mean years+SE) 31.69+0.72 38.26+0.72 T = −4.49 0.0001 
BMI (mean score+SE) 27.46+0.45 30.08+0.38 T = −4.42 0.0001 
Maternal education (mean years+SE) 13.81+0.17 12.93+0.15 T = 3.92 0.0001 
Race, n (% Black) 88 (37.77) 167 (49.85) χ2 = 8.11 0.004 
RBANS (mean score+SE) 84.96+0.76 64.26+0.64 T = 20.73 0.0001 
Sex, n (% female) 134 (57.51) 123 (36.72) χ2 = 23.99 0.001 
Smoker, n (%) 37 (15.88) 200 (59.70) χ2 = 108.53 0.001 
Sociodemographic/other test variableNCs (n = 233)SCH (n = 335)Test statp value
Age (mean years+SE) 31.69+0.72 38.26+0.72 T = −4.49 0.0001 
BMI (mean score+SE) 27.46+0.45 30.08+0.38 T = −4.42 0.0001 
Maternal education (mean years+SE) 13.81+0.17 12.93+0.15 T = 3.92 0.0001 
Race, n (% Black) 88 (37.77) 167 (49.85) χ2 = 8.11 0.004 
RBANS (mean score+SE) 84.96+0.76 64.26+0.64 T = 20.73 0.0001 
Sex, n (% female) 134 (57.51) 123 (36.72) χ2 = 23.99 0.001 
Smoker, n (%) 37 (15.88) 200 (59.70) χ2 = 108.53 0.001 

Maternal education was used as a surrogate variable for socioeconomic status.

NCs, nonpsychiatric comparison subjects; SCH, schizophrenia; Test stat, test statistic; BMI, body mass index; RBANS, repeatable battery for the assessment of neuropsychological status.

As described previously [57, 58], individuals received DSM-IV-TR diagnoses of schizophrenia, schizophreniform, or schizoaffective disorders [59] and were between the ages of 18 and 65. Cognitive functioning was examined with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Form A [60]. The comparison group was composed of individuals who did not have a history of psychiatric disorder based on the Structured Clinical Interview for DSM-IV Axis I Disorders Non-Patient Edition [61]. Exclusion criteria for both groups were the following: mental retardation; clinically significant medical disorder that would affect cognitive performance; any history of intravenous substance abuse or a primary diagnosis of substance abuse or substance dependence. For the comparison group, any active substance misuse was considered an exclusion criterion.

We received approval for these studies by the Institutional Review Boards (IRB) of Sheppard Pratt and the Johns Hopkins Medical Institution following established guidelines. Written informed consent was obtained from all participants after study procedures were explained. This research was performed in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

Laboratory Tests

Blood was drawn at the time of interview using Becton-Dickinson’s Cell Preparation Tubes containing sodium citrate. Plasma was separated and stored at −80°C for the blood biomarker studies. Peripheral blood mononuclear cells were isolated and stored at −80°C for the C4 gene marker studies.

C4 genotyping was performed on 108 individuals in the sychiatric comparison group and on 168 individuals with schizophrenia. For C4 genotyping, DNA was extracted from peripheral blood mononuclear cells using Qiagen’s DNAeasy kit and stored at −80°C. Complement C4A, C4B, C4S, and C4L CNVs were imputed from GWAS SNPs data using previously described methods including use of DNA microarrays on the extracted DNA (Sekar et al. [28]; https://github.com/freeseek/imputec4). Utilized SNP chips were PsychChip (PsychChip_15048346), Omni2.5 (HumanOmni25M-8v1-1), and GSA (GSAMD-24v1-0_20011747).

To examine plasma C4 associations with other plasma immune-related variables, we searched our database and selected the following targets: 5 autoimmune markers (double-stranded DNA [dsDNA IgG], an often-used biomarker for lupus [62], the Celiac disease-associated tissue-transglutaminase (TTG) IgA, IgG, and gliadin food antigen IgG [63], and NMDAR-NR2 subunit IgG, an autoantibody target often studied in psychoses and schizophrenia and related models [64‒66]); 4 markers of past infectious events with selections representing different taxa of pathogens (fungi (C. albicans IgG) [67], viruses (cytomegalovirus [CMV], EBV IgG) and a parasite (T. gondii IgG) [68], which is also cross-listed in the GI category, because infection produces GI inflammation [69]); 5 indices of GI inflammation or dysbiosis (gliadin IgG (cross-listed as an autoantibody target) [70], bacteria-associated lipopolysaccharide (LPS)-binding protein and its inflammation partner, sCD14 (a marker of monocyte response to LPS and also cross-listed as an inflammatory marker) [71], translocation of the dietary yeast, Saccharomyces cerevisiae, used to help diagnose Crohn’s Disease [72], and T. gondii IgG, cross-listed as a pathogen); and C-reactive protein (CRP) and sCD14 (cross-listed with GI) used as basic measures of inflammation [58, 73].

Plasma biomarker quantification was performed using commercially available enzyme-linked immunosorbent assays (ELISAs). Total C4 protein in plasma was measured using the ELISA kit manufactured by Abcam (catalog# ab108824, Waltham, MA, USA). The methods, ELISA kit sources, and statistical analyses to distinguish psychiatric case and comparison group levels of the other targeted biomarkers have been previously described for all except the dsDNA IgG [63, 67, 68, 71, 72, 74‒76]. The ELISA kit targeting the biomarker, dsDNA IgG, was purchased from IBL America, Minneapolis, MN, USA (catalog# ORG 604).

Data Analyses

ANOVAs with post hoc Sidak analyses and t tests were used to detect bivariate associations between continuous variables, such as the baseline C4 plasma levels between individuals with SCH and NCs. χ2 analyses were used to detect bivariate associations between categorical variables such as race and sex differences in SCH and NCs.

Multiple linear regression models were used to examine correlations among continuous variables such as C4 plasma levels with C4 CNVs, antibodies, and other biomarker levels. Biomarker positivity was defined based on quantitative levels of these markers in NCs. Biomarker values in the SCH population which exceeded the 90th percentile of NCs values were considered seropositive. Multivariate linear regressions included the covariates: age, BMI, maternal education (surrogate for socioeconomic status), race, sex, and tobacco smoking. An assay plate covariate was included in the ELISA data analyses regression models to correct for plate-to-plate variation. These regressions were performed both with and without robust standard error correction, a statistical test increasingly applied to maximize additional clustered data that we had for each individual in the form of repeated outcome measurements over time [77]. We did not formally account for multiple comparisons due to the exploratory nature of the study and to minimize the occurrence of type B (false negative) errors. Thus, a p value of less than 0.05 was considered significant.

Plasma C4 and General/Systemic Inflammation

Plasma C4 levels in SCH were not significantly different from those in the non-psychiatric comparison group (NCs: n = 233; mean + SE = 1.23 + 0.07 μg/mL; SCH: n = 335; mean + SE = 1.32 + 0.05 μg/mL; T test t = −1.01, p > 0.15; ANOVA F = 1.02, p > 0.31). In contrast, plasma levels of the general marker for inflammation, CRP, were significantly elevated in SCH compared to NCs (NCs: 0.55 + 0.04 optical density units (od); SCH: 0.84 + 0.04 od; T test t = −4.55, p < 0.0001; ANOVA F = 20.74, p < 0.0001). In both NCs and SCH, plasma C4 levels were well-correlated with plasma CRP levels in multiple linear regressions that included age, BMI, maternal education, race, sex, and smoking (NCs: n = 233; R coefficient = 0.30, CI = 0.09–0.51, R2 = 0.12, p < 0.0003; SCH: n = 335; R coefficient = 0.24, CI = 0.11–0.37, R2 = 0.09, p < 0.0002).

Plasma C4 and C4 Gene Copy Number Variants

In multiple linear regressions, C4A CNVs were significantly associated with C4 plasma levels in NCs but not in SCH (Table 2; NCs: n = 108; R coefficient = 0.39, CI = 0.01–0.77, R2 = 0.18, p < 0.01; SCH: n = 168; R coefficient = −0.03, CI = −0.27 to 0.21, R2 = 0.06, p > 0.79). C4B, C4L, and C4S CNVs were not significantly associated with plasma C4 in either NCs or SCH (All p > 0.27).

Table 2.

Multivariate regressions of C4 gene copy number variants with plasma C4

NCs (n = 108)SCH (n = 168)
Genetic test variable (C4 CNVs)R coeff95th% CIR2p valueR coeff95th% CIR2p value
C4A 0.39 0.01–0.77 0.18 0.01 −0.03 −0.27 to 0.21 0.06 >0.79 
C4B −0.17 −0.68 to 0.35 0.15 >0.52 −0.03 −0.34 to 0.29 0.06 >0.86 
C4L 0.04 −0.22 to 0.30 0.15 >0.75 −0.09 −0.26 to 0.07 0.07 >0.27 
C4S 0.12 −0.18 to 0.41 0.15 >0.45 0.10 −0.10 to 0.31 0.06 >0.31 
NCs (n = 108)SCH (n = 168)
Genetic test variable (C4 CNVs)R coeff95th% CIR2p valueR coeff95th% CIR2p value
C4A 0.39 0.01–0.77 0.18 0.01 −0.03 −0.27 to 0.21 0.06 >0.79 
C4B −0.17 −0.68 to 0.35 0.15 >0.52 −0.03 −0.34 to 0.29 0.06 >0.86 
C4L 0.04 −0.22 to 0.30 0.15 >0.75 −0.09 −0.26 to 0.07 0.07 >0.27 
C4S 0.12 −0.18 to 0.41 0.15 >0.45 0.10 −0.10 to 0.31 0.06 >0.31 

CNV, copy number variant; NCs, nonpsychiatric comparison subjects; SCH, schizophrenia; R coeff, regression coefficient; CI, confidence interval.

Regressions included all variables found in Table 1.

Plasma C4 and Basic Sociodemographic and Clinical Variables

For these analyses, we first sought to identify if C4 plasma levels were associated with those sociodemographic and other variables that are commonly used to protect multivariate comparisons from confounding factors. Second, we have multiple samples per individual and wanted to maximize our ability to identify a C4 association if one were present. Therefore, we first compared analyses done using the standard dataset composed of one sample per individual (n = 233 NC; n = 335 SCH). We then applied robust standard errors to our regression models to accommodate additional data from those individuals for whom we had multiple samples per individual (n = 290 NCs samples; n = 630 SCH samples).

In multiple linear regressions, BMI and sex were significantly associated with C4 plasma levels in NCs using the standard sample size analysis (p < 0.003); the inclusion of robust standard error analyses confirmed these significant associations of C4 with BMI and sex and also identified an association with race (all p < 0.0001). In SCH, analyses of both sample sizes identified BMI and race as having significant associations with C4 plasma levels (p < 0.0009–0.02). These data are shown in Table 3.

Table 3.

Multivariate regressions of sociodemographic and related study variables with plasma C4

NCsSCH
Sociodem/other test variablenR95th% CIR2p valuenR95th% CIR2p value
 Individuals          
Age 233 −0.01 −0.02 to 0.01 0.09 >0.63 335 0.01 −0.01 to 0.01 0.05 >0.46 
BMI 233 0.03 0.01–0.05 0.09 0.003 335 0.02 0.01–0.04 0.05 0.02 
Maternal education 233 0.04 −0.02 to 0.09 0.09 >0.18 335 0.01 −0.03 to 0.05 0.05 >0.61 
Race 233 0.25 −0.04 to 0.53 0.09 >0.09 335 0.24 0.03–0.45 0.05 0.02 
Sex 233 −0.37 −0.63 to 0.12 0.09 0.003 335 0.21 −0.02 to 0.42 0.05 >0.07 
Smoker 233 −0.01 −0.36 to 0.35 0.09 >0.96 335 −0.01 −0.23 to 0.20 0.05 >0.92 
 Samples          
Age 290 −0.01 −0.01 to 0.01 0.08 >0.87 630 −0.01 −0.01 to 0.01 0.05 >0.96 
BMI 290 0.03 0.01–0.04 0.08 0.0001 630 0.02 0.01–0.03 0.05 0.0009 
Maternal education 290 0.01 −0.04 to 0.06 0.08 >0.65 630 0.01 −0.03 to 0.05 0.05 >0.71 
Race 290 0.32 0.04–0.60 0.08 0.0001 630 0.27 0.08–0.46 0.05 0.0009 
Sex 290 −0.33 −0.58 to 0.07 0.08 0.0001 630 0.14 −0.06 to 0.33 0.05 >0.17 
Smoker 290 0.04 −0.31 to 0.39 0.08 >0.82 630 −0.11 −0.30 to 0.07 0.05 >0.24 
NCsSCH
Sociodem/other test variablenR95th% CIR2p valuenR95th% CIR2p value
 Individuals          
Age 233 −0.01 −0.02 to 0.01 0.09 >0.63 335 0.01 −0.01 to 0.01 0.05 >0.46 
BMI 233 0.03 0.01–0.05 0.09 0.003 335 0.02 0.01–0.04 0.05 0.02 
Maternal education 233 0.04 −0.02 to 0.09 0.09 >0.18 335 0.01 −0.03 to 0.05 0.05 >0.61 
Race 233 0.25 −0.04 to 0.53 0.09 >0.09 335 0.24 0.03–0.45 0.05 0.02 
Sex 233 −0.37 −0.63 to 0.12 0.09 0.003 335 0.21 −0.02 to 0.42 0.05 >0.07 
Smoker 233 −0.01 −0.36 to 0.35 0.09 >0.96 335 −0.01 −0.23 to 0.20 0.05 >0.92 
 Samples          
Age 290 −0.01 −0.01 to 0.01 0.08 >0.87 630 −0.01 −0.01 to 0.01 0.05 >0.96 
BMI 290 0.03 0.01–0.04 0.08 0.0001 630 0.02 0.01–0.03 0.05 0.0009 
Maternal education 290 0.01 −0.04 to 0.06 0.08 >0.65 630 0.01 −0.03 to 0.05 0.05 >0.71 
Race 290 0.32 0.04–0.60 0.08 0.0001 630 0.27 0.08–0.46 0.05 0.0009 
Sex 290 −0.33 −0.58 to 0.07 0.08 0.0001 630 0.14 −0.06 to 0.33 0.05 >0.17 
Smoker 290 0.04 −0.31 to 0.39 0.08 >0.82 630 −0.11 −0.30 to 0.07 0.05 >0.24 

Sociodem, sociodemographic; n, sample size; NCs, nonpsychiatric comparison subjects; SCH, schizophrenia; R, regression coefficient; CI, confidence interval.

Regressions included all variables found in Table 1.

We further characterized these sociodemographic associations and found that C4 plasma levels were elevated in individuals who were Black in both the NCs and SCH groups (NCs: n = 88 Black, 1.43 + 0.11, n = 145 non-Black, 1.11 + 0.08; T = −2.33, 1-tail p < 0.01; SCH: n = 167 Black, 1.44 + 0.07, n = 168 non-Black, 1.19 + 0.07; T = −2.35, 1-tail p < 0.01), and in females of the NCs (n = 134 females, 1.38 + 0.08, n = 99 males, 1.03 + 0.11, T = 2.58, 1-tail p < 0.005). C4 plasma levels were not significantly correlated with RBANS measures of cognitive functioning in either SCH or NCs (all >0.05).

Plasma C4 and Immune-Related Variables

We detected numerous associations of plasma C4 with other immune-related plasma biomarkers, and this complete dataset is shown in Table 4. Further description of these findings is present in the next section.

Table 4.

Multivariate regressions of immune-related plasma biomarkers with plasma C4

NCsSCH
Immune-related test variablenR95th% CIR2p valuenR95th% CIR2p value
Autoimmune           
 dsDNA IgG 82 3.07 0.60–5.53 0.32 0.0001 260 −1.20 −2.63 to 0.23 0.07 0.10 
 Gliadin IgGa 290 −0.31 −1.11 to 0.49 0.09 0.45 630 0.08 −0.06 to 0.23 0.05 0.26 
 NMDAR-NR2 IgG 290 −0.38 −0.50 to 0.26 0.23 0.0001 630 −0.39 −0.48 to 0.3 0.18 0.0001 
 Tissue transglutaminase IgA 202 0.15 0.06–0.25 0.16 0.0001 380 −0.55 −1.13 to 0.03 0.15 0.0001 
 Tissue transglutaminase IgG 202 0.22 0.07–0.37 0.17 0.0001 380 −0.04 −0.64 to 0.56 0.14 0.90 
Infection 
C. albicans IgG 290 0.20 −0.11 to 0.52 0.09 0.20 630 0.08 −0.08 to 0.25 0.05 0.33 
 CMV IgG 290 0.13 0.02–0.24 0.10 0.0001 630 0.08 −0.01 to 0.17 0.06 0.07 
 EBV IgG 290 −0.06 −0.29 to 0.18 0.09 0.64 630 0.10 −0.07 to 0.27 0.05 0.26 
T. gondii IgGa 290 0.13 −0.07 to 0.33 0.09 0.19 630 0.30 0.12–0.49 0.06 0.001 
Gastrointestinal 
 Gliadin IgGa 290 −0.31 −1.11 to 0.49 0.09 0.45 630 0.08 −0.06 to 0.23 0.05 0.26 
 LBP 290 0.05 0.04–0.06 0.26 0.0001 630 0.03 0.03–0.04 0.17 0.0001 
S. cerevisiae IgG 290 0.13 −0.13 to 0.39 0.09 0.33 630 0.02 −0.13 to 0.18 0.05 0.77 
 sCD14a 290 0.66 0.56–0.75 0.47 0.0001 630 0.46 0.39–0.52 0.31 0.0001 
T. gondii IgGa 290 0.13 −0.07 to 0.33 0.09 0.19 630 0.30 0.12–0.49 0.06 0.001 
Other inflammation 
 CRP (general) 290 0.35 0.17–0.53 0.13 0.0001 630 0.23 0.13–0.33 0.08 0.0001 
 sCD14a (monocyte activation) 290 0.66 0.56–0.75 0.47 0.0001 630 0.46 0.39–0.52 0.31 0.0001 
NCsSCH
Immune-related test variablenR95th% CIR2p valuenR95th% CIR2p value
Autoimmune           
 dsDNA IgG 82 3.07 0.60–5.53 0.32 0.0001 260 −1.20 −2.63 to 0.23 0.07 0.10 
 Gliadin IgGa 290 −0.31 −1.11 to 0.49 0.09 0.45 630 0.08 −0.06 to 0.23 0.05 0.26 
 NMDAR-NR2 IgG 290 −0.38 −0.50 to 0.26 0.23 0.0001 630 −0.39 −0.48 to 0.3 0.18 0.0001 
 Tissue transglutaminase IgA 202 0.15 0.06–0.25 0.16 0.0001 380 −0.55 −1.13 to 0.03 0.15 0.0001 
 Tissue transglutaminase IgG 202 0.22 0.07–0.37 0.17 0.0001 380 −0.04 −0.64 to 0.56 0.14 0.90 
Infection 
C. albicans IgG 290 0.20 −0.11 to 0.52 0.09 0.20 630 0.08 −0.08 to 0.25 0.05 0.33 
 CMV IgG 290 0.13 0.02–0.24 0.10 0.0001 630 0.08 −0.01 to 0.17 0.06 0.07 
 EBV IgG 290 −0.06 −0.29 to 0.18 0.09 0.64 630 0.10 −0.07 to 0.27 0.05 0.26 
T. gondii IgGa 290 0.13 −0.07 to 0.33 0.09 0.19 630 0.30 0.12–0.49 0.06 0.001 
Gastrointestinal 
 Gliadin IgGa 290 −0.31 −1.11 to 0.49 0.09 0.45 630 0.08 −0.06 to 0.23 0.05 0.26 
 LBP 290 0.05 0.04–0.06 0.26 0.0001 630 0.03 0.03–0.04 0.17 0.0001 
S. cerevisiae IgG 290 0.13 −0.13 to 0.39 0.09 0.33 630 0.02 −0.13 to 0.18 0.05 0.77 
 sCD14a 290 0.66 0.56–0.75 0.47 0.0001 630 0.46 0.39–0.52 0.31 0.0001 
T. gondii IgGa 290 0.13 −0.07 to 0.33 0.09 0.19 630 0.30 0.12–0.49 0.06 0.001 
Other inflammation 
 CRP (general) 290 0.35 0.17–0.53 0.13 0.0001 630 0.23 0.13–0.33 0.08 0.0001 
 sCD14a (monocyte activation) 290 0.66 0.56–0.75 0.47 0.0001 630 0.46 0.39–0.52 0.31 0.0001 

n, sample size; NCs, nonpsychiatric comparison subjects; SCH, schizophrenia; R, regression coefficient; CI, confidence interval; dsDNA, double-stranded DNA; NMDAR-NR2, N-methyl-D-aspartate receptor-NR2 subunit; CMV, cytomegalovirus; EBV, Epstein-Barr virus; LPS, lipopolysaccharide; LBP, lipopolysaccharide-binding protein; sCD14, soluble CD14; CRP, C-reactive protein.

Regressions included all variables found in Table 1.

aCross-listed in multiple categories.

Summary of Plasma C4 with All Variable Types

As depicted in Table 5, we categorized the variables examined in this study according to if the C4 association was in (1) neither SCH nor NCs, (2) both SCH and NCs, (3) either SCH or NCs. We expected the last category to be the most informative since it would presumably identify differential C4 plasma levels between NCs and individuals with SCH. However, the C4 associations in both NCs and SCH are also informative as variables that might require matching in future studies.

Table 5.

Summary of plasma C4 associated variables in and out of schizophrenia

Test variablePresence of significant association
NEITHER NCs nor SCHBOTH NCs and SCHEITHER NCs or SCHb
p valuep valuep value
Sociodemographic/other 
 Age NS   
 BMI  0.0001–0.0009  
 Maternal education NS   
 Race  0.0001–0.0009  
 Sex   NCs: 0.0001 
 Smoker NS   
C4 gene CNVs 
 C4A   NCs: 0.01 
 C4B NS   
 C4L NS   
 C4S NS   
Autoimmune 
 dsDNA IgG   NCs: 0.0001 
 Gliadin IgGa NS   
 NMDAR-NR2 IgG  Both 0.0001  
 Tissue transglutaminase IgA  Both 0.0001  
 Tissue transglutaminase IgG   NCs: 0.0001 
Infection 
C. albicans IgG NS   
 CMV IgG   NCs: 0.0001 
 EBV IgG NS   
T. gondiia IgG   SCH: 0.0001 
Gastrointestinal 
 Gliadin IgGa NS   
 LBP  Both 0.0001  
S. cerevisiae IgG NS   
 sCD14a  Both 0.0001  
T. gondii IgGa   SCH: 0.001 
Other inflammation 
 CRP  Both 0.0001  
 sCD14a  Both 0.0001  
Test variablePresence of significant association
NEITHER NCs nor SCHBOTH NCs and SCHEITHER NCs or SCHb
p valuep valuep value
Sociodemographic/other 
 Age NS   
 BMI  0.0001–0.0009  
 Maternal education NS   
 Race  0.0001–0.0009  
 Sex   NCs: 0.0001 
 Smoker NS   
C4 gene CNVs 
 C4A   NCs: 0.01 
 C4B NS   
 C4L NS   
 C4S NS   
Autoimmune 
 dsDNA IgG   NCs: 0.0001 
 Gliadin IgGa NS   
 NMDAR-NR2 IgG  Both 0.0001  
 Tissue transglutaminase IgA  Both 0.0001  
 Tissue transglutaminase IgG   NCs: 0.0001 
Infection 
C. albicans IgG NS   
 CMV IgG   NCs: 0.0001 
 EBV IgG NS   
T. gondiia IgG   SCH: 0.0001 
Gastrointestinal 
 Gliadin IgGa NS   
 LBP  Both 0.0001  
S. cerevisiae IgG NS   
 sCD14a  Both 0.0001  
T. gondii IgGa   SCH: 0.001 
Other inflammation 
 CRP  Both 0.0001  
 sCD14a  Both 0.0001  

NCs, nonpsychiatric comparison subjects; SCH, schizophrenia; NS, not significant; dsDNA, double-stranded DNA; NMDAR-NR2, N-methyl-D-aspartate receptor-NR2 subunit; CMV, cytomegalovirus; EBV, Epstein-Barr virus; LPS, lipopolysaccharide; LBP, lipopolysaccharide-binding protein; sCD14, soluble CD14; CRP, C-reactive protein.

aCross-listed in multiple categories.

bPotentially diagnostic.

Variables associated with plasma C4 levels in both SCH and NCs included BMI, race, NMDAR-NR2 IgG, TTG IgA, LBP, SCD14, and CRP. Variables that were differentially associated with C4 levels in SCH versus NCs included sex, C4A CNV, dsDNA IgG, TTG IgG, CMV IgG, and T. gondii IgG. In this latter category, only the levels of T. gondii antibodies were positively associated with plasma C4 levels in schizophrenia; the remainder was associated with plasma C4 in the NCs. Most of the correlations detected in this study were positive except for the autoimmune variables, NMDAR-NR2, and tissue-transglutaminase autoantibodies which showed various patterns of inverse correlations with plasma C4. We further explored this autoimmune association in schizophrenia and found that when we removed individuals who were positive for the NMDAR-NR2 autoantibodies (n = 22), circulating C4 levels were significantly elevated compared to the NCs (NCs: n = 233, 1.23 + 0.07 μg/mL; SCH: n = 313, 1.42 + 0.05 μg/mL; ANOVA, F = 5.16, p < 0.02). Removal of individuals with schizophrenia who were seropositive for each of the other autoimmune markers did not similarly restore plasma C4 level differences between SCH and NCs.

In this exploratory study, we report on a complex dynamic of sociodemographic, genetic, autoimmune, infectious, GI, and inflammatory factors that may influence plasma complement C4 levels relevant to schizophrenia. Complement activities in the circulatory system are primarily known to us in an immune context where complement molecules and pathways function to remove pathogens and cellular debris from our bodies. This innate immune response is characterized by a pro-inflammatory environment that subsides when the threat is gone [23]. An abnormally sustained chronic inflammatory period is a pathology that is increasingly reported in a subset of individuals with schizophrenia [14, 78, 79].

Our first step to evaluate plasma C4 as a potential biomarker was to assess baseline differences in a known C4 phenotype, peripheral inflammation [17], between individuals with schizophrenia and a nonpsychiatric comparison group. We found no significant differences between plasma C4 levels of individuals with schizophrenia and the comparison group, in direct contrast to a routinely used marker of inflammation, plasma CRP levels, which were significantly elevated in people with schizophrenia. These preliminary findings suggest that inflammation of some type was differentially present in schizophrenia and was detectable by the CRP. The failure of C4 to also detect this inflammation may suggest the presence of a different immunopathology and possibly other operative mechanism driving down plasma C4 levels.

In addition to its classic role removing pathogens and cellular debris, the complement system, when dysregulated, impaired, or mis-activated, has been shown to contribute to autoimmune disorders, and also increasingly to neurological disorders [80, 81]. Using multivariate regression models, we found that autoimmune markers and particularly autoantibodies directed against the NMDAR-NR2 subunit were associated with decreased plasma C4 levels. This finding is not surprising given that epidemiology studies have identified a significant autoimmune component comorbid to schizophrenia in some individuals [66, 82, 83]. Of further note, alterations of complement system factors, including plasma C4, can help diagnose suspected cases of autoimmunity [84]. It is possible that if peripheral C4A is upregulated as a function of high C4A gene CNVs, it may not always be observed peripherally due to masking by an undetectable saturation/consumption of C4 during an autoimmune event. This possibility should be examined in future longitudinal studies prospectively designed to trace plasma C4 changes over time in populations of individuals with SCH with and without known autoimmune comorbidities.

The associations of peripheral C4 with many diverse types of markers in both diagnostic groups motivated us to also look for other factors that may mediate apparent decreases of plasma C4. C4 gene deficiencies such as C4 null alleles may be prime candidates to interrogate in future studies, as these mutations are known to lead to autoimmune susceptibilities, as are C4B partial or complete deficiencies [19, 21, 33, 84]. It is of note that the ancestral human leukocyte antigen (HLA) 8.1 haplotype, one of the most associated haplotypes with autoimmune disorders, is thought to be protective against schizophrenia likely due to its natural lack of the C4A locus [28, 85, 86]. We examined CNVs of the C4 gene with the expectation that a high copy number would lead to elevated plasma C4 levels. Conversely, a low CNV (the closest we can come to in this study to a null allele) would in turn be hypothesized to associate with a low plasma C4 level. We found that C4A CNVs were positively correlated with levels of plasma C4 in NCs only, suggesting that a direct linear relationship between the number of C4A CNVs and plasma C4 levels in controls may be disrupted in schizophrenia. We re-analyzed these data with the NMDAR-NR2 autoantibody-seropositive individuals removed; however, the linear correlation of plasma C4 and C4A CNV variables was not restored (data not shown), suggesting that other factors may be operative.

Overall, these results further highlight that conditions leading to and expressed as inflammation may be highly heterogeneous. In addition to sociodemographic, genetic, and autoimmune markers, other indices including those derived from infectious disease sources and gut dysbiosis were found to be associated with plasma C4 patterns. Exposure to T. gondii, as measured by IgG antibodies, was the only marker that was significantly correlated with plasma C4 in schizophrenia but not the comparison group. Of note, T. gondii is a pathogen that is not only neurotropic, but it enters the host through ingestion and creates an inflammatory environment in the GI tract [69]. For this reason, we cross-listed T. gondii in the gut dysbiosis category. The viral marker, CMV IgG, was correlated with plasma C4 only in controls, suggesting that in schizophrenia, this linear relationship is disrupted, as similar to our observations of C4A copy number correlations with plasma C4 only in controls. More in-depth mechanistic studies are certainly required, but one explanation may be that these pathogens evade host immune systems in different ways, such as through complement regulation and inactivation [87‒89].

A long-term goal of these studies is to better understand if the complement system can be harnessed to serve as a biomarker of neuroinflammation, synaptic pruning or even if complement pathways can be modulated for therapeutic use. Recent evidence, for example, supports a complement and coagulation protein pathway mechanism by which omega-3 polyunsaturated fatty acids might contribute to cognitive and symptom improvements in individuals with early psychosis [41]. A role for C4 in neuroinflammation is based on positive, negative, and mixed associations of C4 levels with markers of white matter integrity, CSF biochemistry, cortical thinning, and patterns of expression with postmortem brain structures and functions [31, 32, 42, 51, 52, 54, 90‒97].

Our study has a number of limitations which further accentuate the very exploratory nature of our findings. Methodologically, we were limited by our measurement of total C4 protein levels in plasma, rather than a separate measurement of plasma C4A and C4B. It is generally difficult to distinguish C4A from C4B using ELISA-based methods, but this limitation was overcome in a recent study that used mass spectrometry to distinguish C4A and C4B components in CSF [52]. Our schizophrenia and comparison groups were significantly different for each sociodemographic measure, which reinforces the importance of having very-well-matched study populations and rigorous statistics to accommodate the many variables that may contribute to a study’s outcome. As a pilot study aimed to assess the prospects of a potential biomarker, we started with variables in our own database. This action might be construed as a biased selection based on convenience, rather than as a carefully constructed and systematic retrospective examination to prepare for future resource-intensive, prospective studies. Furthermore, individuals in our schizophrenia group were not medication-naïve. In a study of persons at high risk for psychosis and those with FEP, treatment with the antipsychotic aripiprazole was associated with decreased C4 plasma levels [98]. In our study, a small number of people (38 of 335 individuals with schizophrenia) were receiving aripiprazole; however, when we removed these individuals from our analyses, levels of plasma C4 between schizophrenia and the comparison group were still not significantly different (data not shown).

There are also more global limitations to consider about the emerging C4 model of schizophrenia. While this C4 model of schizophrenia has advanced the field technically and philosophically, substantial gaps in our knowledge of the pathophysiological steps that lead to schizophrenia are still present [33, 34, 42, 99]. For example, C4A genomic diversity and inferred C4 expression do not always equate with a risk of schizophrenia independently of the immune-gene rich major histocompatibility complex region or outside of European and African populations [55, 99, 100]. Furthermore, a role for synaptic pruning mechanisms attributable to C4 is predominantly based on experiments performed in rodent models, whose single C4 gene is not structurally homologous to the two-gene human C4 system [28, 34, 101] but see [52, 102]. C4A expression in the human brain was in part based on work that may have included diagnostically heterogeneous control groups. Big data investigations further indicate that schizophrenia risk may be preferentially conferred not by genes of the complement system but by synaptic pathways [103]. Strong associations of the complement system with measures of cognitive function may also operate independently of C4A allelic diversity [104].

At this research stage, it is currently unknown if plasma C4 is best considered a biomarker of a peripheral inflammation subtype or if it may have more far-reaching applicability to reflect CNS functions. The identification of autoantibodies that were associated with decreased plasma C4 measures serves as one example of how we may better balance population comparisons of plasma C4 by pre-identifying individuals with any evidence of autoimmune issues. Likewise, balancing population comparisons for pathogen exposures such as T. gondii, which were associated with plasma C4 levels in schizophrenia, may help further refine these analyses. Follow-up studies that directly examine C4 associations with T. gondii, with autoimmunity, and with the other significant variables found in Table 5 in larger cohorts of individuals with schizophrenia are certainly needed. Incorporating machine learning algorithms that model and predict outcome risks based on variable relatedness and interactions show promise for evaluating complex target such as plasma C4, but regression models are still a gold standard [105]. It is clear that the variation in plasma C4 derives from complex sources and that some variables contribute positively to plasma C4 levels and others contribute negatively. In this pilot study, we share a baseline collection of knowledge to assess if plasma C4 is transformable into an informative biomarker relevant to schizophrenia.

As stated in the Materials and Methods section describing the study population, approval for these studies was granted by the Institutional Review Boards (IRB) of Sheppard Pratt and the Johns Hopkins Medical Institution following established guidelines. The Sheppard Pratt IRB Review Committee reviewed and approved two study protocols, with the approval numbers, 767141-23 and 332263-25, and approval dates, December 15, 2022, and May 11, 2023, respectively. The Johns Hopkins School of Medicine IRB-X Committee reviewed and approved one study protocol, approval number CR00042820/NA_00003294 and approval date, October 31, 2022. Written informed consent was obtained from all participants after study procedures were explained. This research was performed in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans.

Dr. Yolken is a member of the Stanley Medical Research Institute Board of Directors and Scientific Advisory Board. The terms of this arrangement are being managed by the Johns Hopkins University in accordance with its conflict of interest policies. None of the other authors report any potential conflicts of interest.

This work was supported by the Stanley Medical Research Institute and ERA-NET NEURON grant ANR-18-0008-01. These funding sources had no role in the preparation of data or writing of the manuscript.

E.G.S. conceived the idea for the paper. E.G.S., E.P., C.L.W., R.T., M.L., F.D., and R.H.Y. developed the conceptual and intellectual content. S.Y., F.L., and A.L. generated and managed the data. All authors helped interpret the data. E.G.S. and E.P. analyzed the data. E.G.S. wrote the first draft of the paper, and all authors participated in writing and reviewing subsequent drafts.

The datasets analyzed for this study are available upon request in compliance with legal issues involving institutional data sharing regulations. Further inquiries can be directed to the corresponding author.

1.
Wahbeh
MH
,
Avramopoulos
D
.
Gene-environment interactions in schizophrenia: a literature review
.
Genes
.
2021
;
12
(
12
):
1850
.
2.
Stilo
SA
,
Murray
RM
.
Non-genetic factors in schizophrenia
.
Curr Psychiatry Rep
.
2019
;
21
(
10
):
100
.
3.
Demjaha
A
,
MacCabe
JH
,
Murray
RM
.
How genes and environmental factors determine the different neurodevelopmental trajectories of schizophrenia and bipolar disorder
.
Schizophr Bull
.
2012
;
38
(
2
):
209
14
.
4.
European Network of National Networks studying Gene-Environment Interactions in Schizophrenia EU-GEI
van Os
J
,
Rutten
BP
,
Myin-Germeys
I
,
Delespaul
P
,
Viechtbauer
W
.
Identifying gene-environment interactions in schizophrenia: contemporary challenges for integrated, large-scale investigations
.
Schizophr Bull
.
2014
;
40
(
4
):
729
36
.
5.
Severance
EG
,
Yolken
RH
.
From infection to the microbiome: an evolving role of microbes in schizophrenia
.
Curr Top Behav Neurosci
.
2020
;
44
:
67
84
.
6.
Kirch
DG
.
Infection and autoimmunity as etiologic factors in schizophrenia: a review and reappraisal
.
Schizophr Bull
.
1993
;
19
(
2
):
355
70
.
7.
Yolken
RH
,
Torrey
EF
.
Are some cases of psychosis caused by microbial agents? A review of the evidence
.
Mol Psychiatry
.
2008
;
13
(
5
):
470
9
.
8.
Benros
ME
,
Nielsen
PR
,
Nordentoft
M
,
Eaton
WW
,
Dalton
SO
,
Mortensen
PB
.
Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study
.
Am J Psychiatry
.
2011
;
168
(
12
):
1303
10
.
9.
Kohler
O
,
Petersen
L
,
Mors
O
,
Mortensen
PB
,
Yolken
RH
,
Gasse
C
.
Infections and exposure to anti-infective agents and the risk of severe mental disorders: a nationwide study
.
Acta Psychiatr Scand
.
2017
;
135
(
2
):
97
105
.
10.
Miller
BJ
,
Graham
KL
,
Bodenheimer
CM
,
Culpepper
NH
,
Waller
JL
,
Buckley
PF
.
A prevalence study of urinary tract infections in acute relapse of schizophrenia
.
J Clin Psychiatry
.
2013
;
74
(
3
):
271
7
.
11.
Torrey
EF
,
Peterson
MR
.
The viral hypothesis of schizophrenia
.
Schizophr Bull
.
1976
;
2
(
1
):
136
46
.
12.
Torrey
EF
,
Bartko
JJ
,
Yolken
RH
.
Toxoplasma gondii and other risk factors for schizophrenia: an update
.
Schizophr Bull
.
2012
;
38
(
3
):
642
7
.
13.
Severance
EG
,
Yolken
RH
.
Deciphering microbiome and neuroactive immune gene interactions in schizophrenia
.
Neurobiol Dis
.
2020
;
135
:
104331
.
14.
Bechter
K
.
Updating the mild encephalitis hypothesis of schizophrenia
.
Prog Neuro-Psychopharmacol Biol Psychiatry
.
2013
;
42
:
71
91
.
15.
Webster
MJ
.
Infections, inflammation, and psychiatric illness: review of postmortem evidence
.
Curr Top Behav Neurosci
.
2023
;
61
:
35
48
.
16.
Severance
EG
,
Leister
F
,
Lea
A
,
Yang
S
,
Dickerson
F
,
Yolken
RH
.
Complement C4 associations with altered microbial biomarkers exemplify gene-by-environment interactions in schizophrenia
.
Schizophr Res
.
2021
;
234
:
87
93
.
17.
Muller
N
.
Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations
.
Schizophr Bull
.
2018
;
44
(
5
):
973
82
.
18.
Mayilyan
KR
.
Complement genetics, deficiencies, and disease associations
.
Protein Cell
.
2012
;
3
(
7
):
487
96
.
19.
Mayilyan
KR
,
Dodds
AW
,
Boyajyan
AS
,
Soghoyan
AF
,
Sim
RB
.
Complement C4B protein in schizophrenia
.
World J Biol Psychiatry
.
2008
;
9
(
3
):
225
30
.
20.
Mayilyan
KR
,
Weinberger
DR
,
Sim
RB
.
The complement system in schizophrenia
.
Drug News Perspect
.
2008
;
21
(
4
):
200
10
.
21.
Rudduck
C
,
Beckman
L
,
Franzen
G
,
Jacobsson
L
,
Lindstrom
L
.
Complement factor C4 in schizophrenia
.
Hum Hered
.
1985
;
35
(
4
):
223
6
.
22.
Rudduck
C
,
Beckman
L
,
Franzen
G
,
Lindstrom
L
.
C3 and C6 complement types in schizophrenia
.
Hum Hered
.
1985
;
35
(
4
):
255
8
.
23.
Murphy
K
,
Travers
P
,
Walport
M
,
Janeway
C
Janeway’s immunobiology
8th ed
New York
Garland Science
2012
. xix, p.
868
.
24.
Severance
EG
,
Gressitt
KL
,
Buka
SL
,
Cannon
TD
,
Yolken
RH
.
Maternal complement C1q and increased odds for psychosis in adult offspring
.
Schizophr Res
.
2014
;
159
(
1
):
14
9
.
25.
Severance
EG
,
Gressitt
KL
,
Halling
M
,
Stallings
CR
,
Origoni
AE
,
Vaughan
C
.
Complement C1q formation of immune complexes with milk caseins and wheat glutens in schizophrenia
.
Neurobiol Dis
.
2012
;
48
(
3
):
447
53
.
26.
Harrison
PJ
.
Recent genetic findings in schizophrenia and their therapeutic relevance
.
J Psychopharmacol
.
2015
;
29
(
2
):
85
96
.
27.
Schizophrenia Working Group of the Psychiatric Genomics Consortium
.
Biological insights from 108 schizophrenia-associated genetic loci
.
Nature
.
2014
;
511
(
7510
):
421
7
.
28.
Sekar
A
,
Bialas
AR
,
de Rivera
H
,
Davis
A
,
Hammond
TR
,
Kamitaki
N
.
Schizophrenia risk from complex variation of complement component 4
.
Nature
.
2016
;
530
(
7589
):
177
83
.
29.
Feinberg
I
.
Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence
.
J Psychiatr Res
.
1982
;
17
(
4
):
319
34
.
30.
van Erp
TGM
,
Walton
E
,
Hibar
DP
,
Schmaal
L
,
Jiang
W
,
Glahn
DC
.
Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium
.
Biol Psychiatry
.
2018
;
84
(
9
):
644
54
.
31.
Prasad
KM
,
Chowdari
KV
,
D’Aiuto
LA
,
Iyengar
S
,
Stanley
JA
,
Nimgaonkar
VL
.
Neuropil contraction in relation to Complement C4 gene copy numbers in independent cohorts of adolescent-onset and young adult-onset schizophrenia patients-a pilot study
.
Transl Psychiatry
.
2018
;
8
(
1
):
134
.
32.
Allswede
DM
,
Zheutlin
AB
,
Chung
Y
,
Anderson
K
,
Hultman
CM
,
Ingvar
M
.
Complement gene expression correlates with superior frontal cortical thickness in humans
.
Neuropsychopharmacology
.
2018
;
43
(
3
):
525
33
.
33.
Woo
JJ
,
Pouget
JG
,
Zai
CC
,
Kennedy
JL
.
The complement system in schizophrenia: where are we now and what’s next
.
Mol Psychiatry
.
2020
;
25
(
1
):
114
30
.
34.
Nimgaonkar
VL
,
Prasad
KM
,
Chowdari
KV
,
Severance
EG
,
Yolken
RH
.
The complement system: a gateway to gene-environment interactions in schizophrenia pathogenesis
.
Mol Psychiatry
.
2017
;
22
(
11
):
1554
61
.
35.
Jenkins
AK
,
Lewis
DA
,
Volk
DW
.
Altered expression of microglial markers of phagocytosis in schizophrenia
.
Schizophr Res
.
2023
;
251
:
22
9
.
36.
Ji
E
,
Boerrigter
D
,
Cai
HQ
,
Lloyd
D
,
Bruggemann
J
,
O'Donnell
M
.
Peripheral complement is increased in schizophrenia and inversely related to cortical thickness
.
Brain Behav Immun
.
2022
;
101
:
423
34
.
37.
Howes
OD
,
Onwordi
EC
.
The synaptic hypothesis of schizophrenia version III: a master mechanism
.
Mol Psychiatry
.
2023
38.
Laskaris
L
,
Zalesky
A
,
Weickert
CS
,
Di Biase
MA
,
Chana
G
,
Baune
BT
.
Investigation of peripheral complement factors across stages of psychosis
.
Schizophr Res
.
2019
;
204
:
30
7
.
39.
Kopczynska
M
,
Zelek
W
,
Touchard
S
,
Gaughran
F
,
Di Forti
M
,
Mondelli
V
.
Complement system biomarkers in first episode psychosis
.
Schizophr Res
.
2019
;
204
:
16
22
.
40.
Mongan
D
,
Sabherwal
S
,
Susai
SR
,
Focking
M
,
Cannon
M
,
Cotter
DR
.
Peripheral complement proteins in schizophrenia: a systematic review and meta-analysis of serological studies
.
Schizophr Res
.
2020
;
222
:
58
72
.
41.
Susai
SR
,
Healy
C
,
Mongan
D
,
Heurich
M
,
Byrne
JF
,
Cannon
M
.
Evidence that complement and coagulation proteins are mediating the clinical response to omega-3 fatty acids: a mass spectrometry-based investigation in subjects at clinical high-risk for psychosis
.
Transl Psychiatry
.
2022
;
12
(
1
):
454
.
42.
Lizano
P
,
Prasad
KM
,
Keshavan
MS
.
Commentary: do Complement factors “connect the dots” in schizophrenia
.
Schizophr Res
.
2019
;
204
:
4
6
.
43.
Mondelli
V
,
Di Forti
M
,
Morgan
BP
,
Murray
RM
,
Pariante
CM
,
Dazzan
P
.
Baseline high levels of complement component 4 predict worse clinical outcome at 1-year follow-up in first-episode psychosis
.
Brain Behav Immun
.
2020
;
88
:
913
5
.
44.
Rey
R
,
Suaud-Chagny
MF
,
Bohec
AL
,
Dorey
JM
,
d’Amato
T
,
Tamouza
R
.
Overexpression of complement component C4 in the dorsolateral prefrontal cortex, parietal cortex, superior temporal gyrus and associative striatum of patients with schizophrenia
.
Brain Behav Immun
.
2020
;
90
:
216
25
.
45.
Chen
S
,
Gou
M
,
Chen
W
,
Xiu
M
,
Fan
H
,
Tan
Y
.
Alterations in innate immune defense distinguish first-episode schizophrenia patients from healthy controls
.
Front Psychiatry
.
2022
;
13
:
1024299
.
46.
Mohd Asyraf
AJ
,
Nour El Huda
AR
,
Hanisah
MN
,
Norsidah
KZ
,
Norlelawati
AT
.
Relationship of selective complement markers with schizophrenia
.
J Neuroimmunol
.
2022
;
363
:
577793
.
47.
Sória
Ld S
,
Gubert
Cd M
,
Cereser
KM
,
Gama
CS
,
Kapczinski
F
.
Increased serum levels of C3 and C4 in patients with schizophrenia compared to eutymic patients with bipolar disorder and healthy
.
Braz J Psychiatry
.
2012
;
34
(
1
):
119
20
.
48.
Ji
RN
,
Zhang
LL
,
Zhao
MF
,
He
HF
,
Bai
W
,
Duan
RX
.
Decreased serum complement component 4 levels in patients with schizophrenia
.
Psychiatr Genet
.
2019
;
29
(
4
):
127
9
.
49.
Idonije
OB
,
Akinlade
KS
,
Ihenyen
O
,
Arinola
OG
.
Complement factors in newly diagnosed Nigerian schizoprenic patients and those on antipsychotic therapy
.
Niger J Physiol Sci
.
2012
;
27
(
1
):
19
21
.
50.
Xia
XW
,
Li
LJ
,
Chen
ZC
,
Qiu
Y
,
Zhao
JS
,
Wu
JY
.
[Correlation of the peripheral serum complement protein levels and cognitive function in first-episode drug-naive patients with schizophrenia]
.
Zhonghua Yixue Zazhi
.
2020
;
100
(
39
):
3081
5
.
51.
Gallego
JA
,
Blanco
EA
,
Morell
C
,
Lencz
T
,
Malhotra
AK
.
Complement component C4 levels in the cerebrospinal fluid and plasma of patients with schizophrenia
.
Neuropsychopharmacology
.
2021
;
46
(
6
):
1140
4
.
52.
Gracias
J
,
Orhan
F
,
Hörbeck
E
,
Holmén-Larsson
J
,
Khanlarkani
N
,
Malwade
S
.
Cerebrospinal fluid concentration of complement component 4A is increased in first episode schizophrenia
.
Nat Commun
.
2022
;
13
(
1
):
6427
.
53.
Cropley
VL
,
Kittel
M
,
Heurich
M
,
Föcking
M
,
Leweke
FM
,
Pantelis
C
.
Complement proteins are elevated in blood serum but not CSF in clinical high-risk and antipsychotic-naïve first-episode psychosis
.
Brain Behav Immun
.
2023
;
113
:
136
44
.
54.
Kamitaki
N
,
Sekar
A
,
Handsaker
RE
,
de Rivera
H
,
Tooley
K
,
Morris
DL
.
Complement genes contribute sex-biased vulnerability in diverse disorders
.
Nature
.
2020
;
582
(
7813
):
577
81
.
55.
Lam
M
,
Chen
CY
,
Li
Z
,
Martin
AR
,
Bryois
J
,
Ma
X
.
Comparative genetic architectures of schizophrenia in East Asian and European populations
.
Nat Genet
.
2019
;
51
(
12
):
1670
8
.
56.
Pariante
CM
,
Carpiniello
B
,
Orrù
MG
,
Sitzia
R
,
Piras
A
,
Farci
AM
.
Chronic caregiving stress alters peripheral blood immune parameters: the role of age and severity of stress
.
Psychother Psychosom
.
1997
;
66
(
4
):
199
207
.
57.
Dickerson
F
,
Stallings
C
,
Origoni
A
,
Katsafanas
E
,
Schweinfurth
LA
,
Savage
CL
.
Pentraxin 3 is reduced in bipolar disorder
.
Bipolar Disord
.
2015
;
17
(
4
):
409
14
.
58.
Dickerson
F
,
Stallings
C
,
Origoni
A
,
Vaughan
C
,
Khushalani
S
,
Yang
S
.
C-reactive protein is elevated in schizophrenia
.
Schizophr Res
.
2013
;
143
(
1
):
198
202
.
59.
APA
Diagnostic and statistical manual of mental disorders : DSM-IV-TR
4th ed
Washington, DC
American Psychiatric Association
2000
. xxxvii. p.
943
.
60.
Randolph
C
RBANS manual: repeatable battery for the assessment of neuropsychological status
San Antonio
Psychological Corporation
1998
.
61.
First
MB
,
Spitzer
RL
,
Gibbon
M
,
Williams
JBW
Structured clinical interview for DSM-IV Axis I disorders: non-patient edition (SCID I/NP)
New York
Biometrics Research, New York State Psychiatric Institute
1998
.
62.
Wang
X
,
Xia
Y
.
Anti-double stranded DNA antibodies: origin, pathogenicity, and targeted therapies
.
Front Immunol
.
2019
;
10
:
1667
.
63.
Dickerson
F
,
Stallings
C
,
Origoni
A
,
Vaughan
C
,
Khushalani
S
,
Leister
F
.
Markers of gluten sensitivity and celiac disease in recent-onset psychosis and multi-episode schizophrenia
.
Biol Psychiatry
.
2010
;
68
(
1
):
100
4
.
64.
Kannan
G
,
Gressitt
KL
,
Yang
S
,
Stallings
CR
,
Katsafanas
E
,
Schweinfurth
LA
.
Pathogen-mediated NMDA receptor autoimmunity and cellular barrier dysfunction in schizophrenia
.
Transl Psychiatry
.
2017
;
7
(
8
):
e1186
.
65.
Li
Y
,
Viscidi
RP
,
Kannan
G
,
McFarland
R
,
Pletnikov
MV
,
Severance
EG
.
Chronic Toxoplasma gondii infection induces anti-N-Methyl-d-Aspartate receptor autoantibodies and associated behavioral changes and neuropathology
.
Infect Immun
.
2018
;
86
(
10
):
e00398
18
.
66.
Severance
EG
,
Dickerson
FB
,
Yolken
RH
.
Autoimmune phenotypes in schizophrenia reveal novel treatment targets
.
Pharmacol Ther
.
2018
;
189
:
184
98
.
67.
Severance
EG
,
Gressitt
KL
,
Stallings
CR
,
Katsafanas
E
,
Schweinfurth
LA
,
Savage
CL
.
Candida albicans exposures, sex specificity and cognitive deficits in schizophrenia and bipolar disorder
.
NPJ Schizophr
.
2016
;
2
:
16018
.
68.
Leweke
FM
,
Gerth
CW
,
Koethe
D
,
Klosterkotter
J
,
Ruslanova
I
,
Krivogorsky
B
.
Antibodies to infectious agents in individuals with recent onset schizophrenia
.
Eur Arch Psychiatry Clin Neurosci
.
2004
;
254
(
1
):
4
8
.
69.
Severance
EG
,
Xiao
J
,
Jones-Brando
L
,
Sabunciyan
S
,
Li
Y
,
Pletnikov
M
.
Toxoplasma gondii-A gastrointestinal pathogen associated with human brain diseases
.
Int Rev Neurobiol
.
2016
;
131
:
143
63
.
70.
Severance
EG
,
Dickerson
F
,
Yolken
RH
.
Complex gastrointestinal and endocrine sources of inflammation in schizophrenia
.
Front Psychiatry
.
2020
;
11
:
549
.
71.
Severance
EG
,
Gressitt
KL
,
Stallings
CR
,
Origoni
AE
,
Khushalani
S
,
Leweke
FM
.
Discordant patterns of bacterial translocation markers and implications for innate immune imbalances in schizophrenia
.
Schizophr Res
.
2013
148
1–3
130
7
.
72.
Severance
EG
,
Alaedini
A
,
Yang
S
,
Halling
M
,
Gressitt
KL
,
Stallings
CR
.
Gastrointestinal inflammation and associated immune activation in schizophrenia
.
Schizophr Res
.
2012
;
138
(
1
):
48
53
.
73.
Osimo
EF
,
Baxter
L
,
Stochl
J
,
Perry
BI
,
Metcalf
SA
,
Kunutsor
SK
.
Longitudinal association between CRP levels and risk of psychosis: a meta-analysis of population-based cohort studies
.
NPJ Schizophr
.
2021
;
7
(
1
):
31
.
74.
Dickerson
F
,
Boronow
J
,
Stallings
C
,
Origoni
A
,
Yolken
R
.
Toxoplasma gondii in individuals with schizophrenia: association with clinical and demographic factors and with mortality
.
Schizophr Bull
.
2007
;
33
(
3
):
737
40
.
75.
Dickerson
F
,
Stallings
C
,
Origoni
A
,
Boronow
J
,
Yolken
R
.
C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia
.
Schizophr Res
.
2007
93
1–3
261
5
.
76.
Kannan
G
,
Crawford
JA
,
Yang
C
,
Gressitt
KL
,
Ihenatu
C
,
Krasnova
IN
.
Anti-NMDA receptor autoantibodies and associated neurobehavioral pathology in mice are dependent on age of first exposure to Toxoplasma gondii
.
Neurobiol Dis
.
2016
;
91
:
307
14
.
77.
Mansournia
MA
,
Nazemipour
M
,
Naimi
AI
,
Collins
GS
,
Campbell
MJ
.
Reflection on modern methods: demystifying robust standard errors for epidemiologists
.
Int J Epidemiol
.
2021
;
50
(
1
):
346
51
.
78.
Feng
T
,
Tripathi
A
,
Pillai
A
.
Inflammatory pathways in psychiatric disorders: the case of schizophrenia and depression
.
Curr Behav Neurosci Rep
.
2020
;
7
(
3
):
128
38
.
79.
Severance
EG
,
Yolken
RH
,
Eaton
WW
.
Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling
.
Schizophr Res
.
2016
;
176
(
1
):
23
35
.
80.
Dalakas
MC
,
Alexopoulos
H
,
Spaeth
PJ
.
Complement in neurological disorders and emerging complement-targeted therapeutics
.
Nat Rev Neurol
.
2020
;
16
(
11
):
601
17
.
81.
Lundtoft
C
,
Pucholt
P
,
Martin
M
,
Bianchi
M
,
Lundström
E
,
Eloranta
ML
.
Complement C4 copy number variation is linked to SSA/ro and SSB/La autoantibodies in systemic inflammatory autoimmune diseases
.
Arthritis Rheumatol
.
2022
;
74
(
8
):
1440
50
.
82.
Benros
ME
,
Eaton
WW
,
Mortensen
PB
.
The epidemiologic evidence linking autoimmune diseases and psychosis
.
Biol Psychiatry
.
2014
;
75
(
4
):
300
6
.
83.
Benros
ME
,
Pedersen
MG
,
Rasmussen
H
,
Eaton
WW
,
Nordentoft
M
,
Mortensen
PB
.
A nationwide study on the risk of autoimmune diseases in individuals with a personal or a family history of schizophrenia and related psychosis
.
Am J Psychiatry
.
2014
;
171
(
2
):
218
26
.
84.
Wang
H
,
Liu
M
.
Complement C4, infections, and autoimmune diseases
.
Front Immunol
.
2021
;
12
:
694928
.
85.
Irish Schizophrenia Genomics Consortium and the Wellcome Trust Case Control Consortium 2
.
Genome-wide association study implicates HLA-C*01:02 as a risk factor at the major histocompatibility complex locus in schizophrenia
.
Biol Psychiatry
.
2012
;
72
(
8
):
620
8
.
86.
Tamouza
R
,
Krishnamoorthy
R
,
Giegling
I
,
Leboyer
M
,
Rujescu
D
.
The HLA 8.1 ancestral haplotype in schizophrenia: dual implication in neuro-synaptic pruning and autoimmunity
.
Acta Psychiatr Scand
.
2020
;
141
(
2
):
169
71
.
87.
Sikorski
PM
,
Commodaro
AG
,
Grigg
ME
.
A protective and pathogenic role for complement during acute Toxoplasma gondii infection
.
Front Cell Infect Microbiol
.
2021
;
11
:
634610
.
88.
Rashidi
S
,
Mansouri
R
,
Ali-Hassanzadeh
M
,
Muro
A
,
Nguewa
P
,
Manzano-Román
R
.
The defensive interactions of prominent infectious Protozoan parasites: the host’s complement system
.
Biomolecules
.
2022
;
12
(
11
):
1564
.
89.
Carrillo
GL
,
Su
J
,
Cawley
ML
,
Wei
D
,
Gill
SK
,
Blader
IJ
.
Complement-dependent loss of inhibitory synapses on pyramidal neurons following Toxoplasma gondii infection
.
J Neurochem
.
2023
90.
North
HF
,
Weissleder
C
,
Fullerton
JM
,
Webster
MJ
,
Weickert
CS
.
Increased immune cell and altered microglia and neurogenesis transcripts in an Australian schizophrenia subgroup with elevated inflammation
.
Schizophr Res
.
2022
;
248
:
208
18
.
91.
Jeppesen
R
,
Orlovska-Waast
S
,
Sørensen
NV
,
Christensen
RHB
,
Benros
ME
.
Cerebrospinal fluid and blood biomarkers of neuroinflammation and blood-brain barrier in psychotic disorders and individually matched healthy controls
.
Schizophr Bull
.
2022
;
48
(
6
):
1206
16
.
92.
Park
J
,
Kang
Y
,
Han
KM
,
Tae
WS
,
Kang
UB
,
Chu
H
.
Association between the C4 binding protein level and white matter integrity in major depressive disorder
.
Psychiatry Investig
.
2022
;
19
(
9
):
703
11
.
93.
Mou
TCM
,
Lane
MV
,
Ireland
DDC
,
Verthelyi
D
,
Tonelli
LH
,
Clark
SM
.
Association of complement component 4 with neuroimmune abnormalities in the subventricular zone in schizophrenia and autism spectrum disorders
.
Neurobiol Dis
.
2022
;
173
:
105840
.
94.
O'Connell
KS
,
Sønderby
IE
,
Frei
O
,
van der Meer
D
,
Athanasiu
L
,
Smeland
OB
.
Association between complement component 4A expression, cognitive performance and brain imaging measures in UK biobank
.
Psychol Med
.
2021
;
52
(
15
):
1
11
.
95.
Lin
L
,
Wu
Y
,
Hang
H
,
Lu
J
,
Ding
Y
.
Plasma complement 3 and complement 4 are promising biomarkers for distinguishing NMOSD from MOGAD and are associated with the blood-brain-barrier disruption in NMOSD
.
Front Immunol
.
2022
;
13
:
853891
.
96.
Purves-Tyson
TD
,
Robinson
K
,
Brown
AM
,
Boerrigter
D
,
Cai
HQ
,
Weissleder
C
.
Increased macrophages and C1qA, C3, C4 transcripts in the midbrain of people with schizophrenia
.
Front Immunol
.
2020
;
11
:
2002
.
97.
Di Biase
MA
,
Geaghan
MP
,
Reay
WR
,
Seidlitz
J
,
Weickert
CS
,
Pébay
A
.
Cell type-specific manifestations of cortical thickness heterogeneity in schizophrenia
.
Mol Psychiatry
.
2022
;
27
(
4
):
2052
60
.
98.
Liu
CM
,
Liu
CC
,
Hsieh
MH
,
Hwang
TJ
,
Lin
YT
,
Chien
YL
.
The plasma level of complement component 4A decreases with aripiprazole treatment in patients with early psychosis
.
Psychiatry Res
.
2022
;
316
:
114775
.
99.
Mariaselvam
CM
,
Wu
CL
,
Boukouaci
W
,
Richard
JR
,
Barau
C
,
Le Corvoisier
P
.
The complement C4 genetic diversity in first episode psychosis of the OPTiMiSE cohort
.
Schizophrenia Bull Open
.
2021
2
1
).
100.
Goff
LM
,
Davies
K
,
Zelek
WM
,
Kodosaki
E
,
Hakim
O
,
Lockhart
S
.
Ethnic differences in complement system biomarkers and their association with metabolic health in men of Black African and White European ethnicity
.
Clin Exp Immunol
.
2023
;
212
(
1
):
52
60
.
101.
Beurskens
FJ
,
Kuenen
JD
,
Hofhuis
F
,
Fluit
AC
,
Robins
DM
,
Van Dijk
H
.
Sex-limited protein: in vitro and in vivo functions
.
Clin Exp Immunol
.
1999
;
116
(
3
):
395
400
.
102.
Sellgren
CM
,
Sheridan
SD
,
Gracias
J
,
Xuan
D
,
Fu
T
,
Perlis
RH
.
Patient-specific models of microglia-mediated engulfment of synapses and neural progenitors
.
Mol Psychiatry
.
2017
;
22
(
2
):
170
7
.
103.
Kim
M
,
Haney
JR
,
Zhang
P
,
Hernandez
LM
,
Wang
LK
,
Perez-Cano
L
.
Brain gene co-expression networks link complement signaling with convergent synaptic pathology in schizophrenia
.
Nat Neurosci
.
2021
;
24
(
6
):
799
809
.
104.
Holland
JF
,
Cosgrove
D
,
Whitton
L
,
Harold
D
,
Corvin
A
,
Gill
M
.
Beyond C4: analysis of the complement gene pathway shows enrichment for IQ in patients with psychotic disorders and healthy controls
.
Genes Brain Behav
.
2019
;
18
(
8
):
e12602
.
105.
Susai
SR
,
Mongan
D
,
Healy
C
,
Cannon
M
,
Cagney
G
,
Wynne
K
.
Machine learning based prediction and the influence of complement: coagulation pathway proteins on clinical outcome: results from the NEURAPRO trial
.
Brain Behav Immun
.
2022
;
103
:
50
60
.